Stock listing

NASDAQ:AMLX Amylyx Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Amylyx Pharmaceuticals, Inc.

Follow Amylyx Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:AMLX

$26.02 USD -0.60 (-2.3%)

Close on Nov 20, 2026

Past year +91.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$25.52 – $26.40 USDNov 20, 2026
Volume
1.14M sharesNov 20, 2026
Market cap
$3.35B USDAt the close on Nov 20, 2026 · price × 128.6M shares outstanding
52-week range
$10.83 – $41.14 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$53.54M USDMedian day 1.38M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Amylyx Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AMLX · Home$26.02 USD-0.60 (-2.3%)1,135,833$25.64$26.40$25.52$26.62Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AMLX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$26.02-0.60-2.3%$25.64$26.40$25.521,135,833
$26.62-0.90-3.3%$27.49$28.17$26.241,510,531
$27.52-0.28-1.0%$27.50$27.66$26.611,175,963
$27.80-2.49-8.2%$30.19$31.35$27.551,578,180
$30.29+0.43+1.4%$29.66$30.72$28.861,618,681
$29.86-1.94-6.1%$31.43$31.57$29.791,473,324
$31.80+0.89+2.9%$31.16$31.88$30.462,001,226
$30.91+0.70+2.3%$29.94$31.22$29.761,424,755
$30.21+0.71+2.4%$29.85$30.32$28.761,297,563
$29.50+1.88+6.8%$27.73$29.58$27.501,860,648
$27.62-1.78-6.1%$30.23$30.23$27.482,210,140
$29.40+0.20+0.7%$30.65$30.68$27.901,586,254
$29.20+1.16+4.1%$28.52$29.46$28.211,202,704
$28.04-0.82-2.8%$28.84$29.51$27.611,161,832
$28.86+0.18+0.6%$28.41$29.09$28.00989,514
$28.68+0.61+2.2%$28.13$29.13$28.10905,442
$28.07-0.23-0.8%$28.11$28.48$27.581,064,464
$28.30+1.21+4.5%$27.28$28.32$26.861,122,468
$27.09-0.11-0.4%$27.25$27.98$26.231,371,103
$27.20-1.37-4.8%$28.46$28.46$27.061,158,793
$28.57-0.46-1.6%$28.84$30.00$28.511,307,959
$29.03+0.26+0.9%$28.96$29.78$28.811,626,560
$28.77+1.44+5.3%$27.54$29.23$27.151,613,173
$27.33+0.99+3.8%$26.48$27.35$26.271,380,993
$26.34-1.31-4.7%$27.65$27.65$26.201,150,596
$27.65+0.62+2.3%$27.68$28.34$27.45882,656
$27.03+0.18+0.7%$26.80$27.77$26.461,166,178
$26.85-0.63-2.3%$27.49$27.69$26.801,059,784
$27.48-0.66-2.3%$28.04$28.49$27.401,106,108
$28.14+0.94+3.5%$27.32$28.60$26.941,471,500
$27.20-0.23-0.8%$27.01$27.53$26.042,622,162
$27.43-0.61-2.2%$27.72$28.46$27.212,056,710
$28.04+0.26+0.9%$27.97$28.50$27.001,279,463
$27.78-0.010.0%$27.92$28.09$27.34941,080
$27.79-0.29-1.0%$28.50$28.81$27.64912,394
$28.08-1.02-3.5%$28.62$29.28$27.551,354,104
$29.10-0.18-0.6%$29.47$29.62$28.641,307,046
$29.28-0.57-1.9%$29.87$30.10$28.991,177,757
$29.85+0.36+1.2%$29.10$30.14$28.711,020,546
$29.49-0.65-2.2%$30.28$30.70$29.471,294,475
$30.14-0.465-1.5%$30.73$31.00$29.831,420,508
$30.61-2.395-7.3%$32.88$33.02$30.531,824,887
$33.00+0.61+1.9%$32.52$33.19$32.251,383,682
$32.39-0.02-0.1%$32.55$33.16$31.901,005,644
$32.41-1.53-4.5%$34.21$34.21$32.252,048,794
$33.94+1.31+4.0%$33.33$34.35$32.951,592,060
$32.63-0.52-1.6%$33.05$33.75$32.101,366,183
$33.15-0.49-1.5%$33.22$33.54$32.361,828,400
$33.64+2.02+6.4%$31.84$33.96$31.571,925,353
$31.62-0.47-1.5%$32.09$33.00$31.371,712,745
$32.09-0.31-1.0%$31.81$32.57$31.441,777,482
$32.40-1.48-4.4%$33.50$34.35$32.301,287,490
$33.88-0.22-0.6%$33.49$34.72$33.101,166,534
$34.10+0.14+0.4%$33.38$34.24$33.38885,518
$33.96-0.53-1.5%$34.49$35.31$33.731,556,792
$34.49+0.68+2.0%$34.00$35.48$34.001,938,485
$33.81+0.06+0.2%$33.49$34.21$32.991,821,535
$33.75-0.99-2.8%$34.77$35.09$32.982,728,978
$34.74-2.44-6.6%$36.78$37.68$34.481,361,802
$37.18+0.10+0.3%$36.75$38.23$36.531,989,242
$37.08-0.38-1.0%$37.13$37.69$35.792,815,491
$37.46-0.69-1.8%$38.50$38.88$36.842,147,376
$38.15-0.51-1.3%$38.64$39.38$37.453,714,467
$38.66-1.00-2.5%$39.80$41.14$38.354,644,894
$39.66+1.06+2.7%$37.49$40.44$37.378,540,882
Ticker
NASDAQ:AMLX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Amylyx Pharmaceuticals, Inc. news

Amylyx Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 141 in all · newest Nov 14, 2026 · oldest 2022
Calls
17 calls with a replay · 17 with a transcript · latest Nov 5, 2026
Decks
11 decks · latest September 2026

Where Amylyx Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AMLX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:AMLXBOATSUnited StatesUSD

Valuation

Price/book 4.4× against a median of 4.1×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.58B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
4.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.21

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLXUS$3.35BUS$2.58Bn/an/an/a4.4×n/a0.0×1.21
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336US$3.57BUS$3.43B7.6×5.1×n/a2.7×69.9%0.0×n/a
Relay Therapeutics, Inc. · NASDAQ:RLAYUS$3.56BUS$2.74Bn/a265×n/a4.3×n/a0.0×1.48
Enliven Therapeutics, Inc. · NASDAQ:ELVNUS$3.42BUS$2.54Bn/an/an/a3.9×n/a0.0×0.89
Disc Medicine, Inc. · NASDAQ:IRONUS$3.42BUS$2.80Bn/an/an/a5.7×n/a0.1×0.94
Viridian Therapeutics, Inc. · NASDAQ:VRDNUS$3.40BUS$2.69Bn/a102×n/a5.9×n/a0.4×1.00
Parabilis Medicines, Inc. · NASDAQ:PBLSUS$3.39BUS$2.53Bn/an/an/a3.4×n/a0.0×n/a
Caliway Biopharmaceuticals Co Ltd · TWSE:6919US$3.38BUS$3.27Bn/an/an/a12.7×n/a0.0×n/a
Iovance Biotherapeutics, Inc. · NASDAQ:IOVAUS$3.19BUS$2.86Bn/a7.5×n/a3.9×−58.2%0.1×1.62
AbCellera Biologics Inc. · NASDAQ:ABCLUS$3.16BUS$2.53Bn/a37.3×n/a3.0×−218.5%0.1×2.42
Viking Therapeutics, Inc. · NASDAQ:VKTXUS$3.16BUS$2.20Bn/an/an/a5.4×n/a0.0×1.31
Median of the othersUS$3.40BUS$2.72B7.6×37.3×4.1×−58.2%0.0×1.31

Forecasts

11 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
43.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.51 · 8 analysts
Revenue, year to Dec 2026
55.56K · 9 analysts

Team and board

Officers

OfficerRole
Josh CohenCo-CEO of Amylyx
Justin KleeCo-CEO of Amylyx
James M. FratesChief Financial Officer
Gina M. MazzarielloChief Legal Officer & General Counsel
Camille L. BedrosianChief Medical Officer
Dan MonahanChief Commercial Officer
Linda A. ArsenaultChief Human Resources Officer
Tom HolmesChief Technical Operations Officer

Board

DirectorRole
George MilneChairman
Bernhardt G. ZeiherDirector
Daphne QuimiDirector
Kari FirestoneDirector
Paul FonteyneDirector

Events

Calls

CallWhenStatus
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2026 Earnings CallThu, Nov 05, 2026 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2026 Earnings CallThu, Aug 06, 2026 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 2026 Earnings CallThu, May 07, 2026 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q4 2025 Earnings CallTue, Mar 03, 2026 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2025 Earnings CallThu, Nov 06, 2025 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2025 Earnings CallThu, Aug 07, 2025 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 2025 Earnings CallThu, May 08, 2025 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q4 2024 Earnings CallTue, Mar 04, 2025 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2024 Earnings CallThu, Nov 07, 2024 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:00 AM ETReplay
All 17 calls
CallWhenStatus
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 2024 Earnings CallThu, May 09, 2024 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q4 2023 Earnings CallThu, Feb 22, 2024 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2023 Earnings CallThu, Nov 09, 2023 · 8:00 AM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2023 Earnings CallThu, Aug 10, 2023 · 4:30 PM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 2023 Earnings CallThu, May 11, 2023 · 4:00 PM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q4 2022 Earnings CallMon, Mar 13, 2023 · 4:30 PM ETReplay
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2022 Earnings CallThu, Nov 10, 2022 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−6.0%
Q2 2026Aug 6, 2026 · Before open+10.7%
Q1 2026May 7, 2026 · Before open−5.3%
Q4 2025Mar 3, 2026 · Before open−7.8%
Q3 2025Nov 6, 2025 · Before open−5.9%
Q2 2025Aug 7, 2025 · Before open−4.3%
Q1 2025May 8, 2025 · Before open−6.0%
Q4 2024Mar 4, 2025+12.0%
Q3 2024Nov 7, 2024 · Before open+5.1%
Q2 2024Aug 8, 2024 · Before open−4.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−2.1%
Q4 2023Feb 22, 2024 · Before open+21.1%
Q3 2023Nov 9, 2023 · Before open−31.9%
Q2 2023Aug 10, 2023 · After close+2.0%
Q1 2023May 11, 2023 · After close−4.0%
Q4 2022Mar 13, 2023 · After close+9.4%
Q3 2022Nov 10, 2022 · After close−3.9%
Q2 2022Aug 11, 2022 · After close−3.6%
Q1 2022May 12, 2022 · After close+13.0%
Q4 2021Mar 30, 2022 · After close−13.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck38 slidesSeptember 2026
Phase 3 LUCIDITY Trial of Avexitide in PBH Topline Data Conference Call (August 2026)Conference17 slidesAug 18, 2026
Investor Presentation (March 2026)Investor deck41 slidesMar 24, 2026
Q4 2025 Earnings PresentationEarnings40 slidesMar 3, 2026
Investor Presentation (January 2026)Investor deck40 slidesJan 8, 2026
Technical Presentation (2025)Technical14 slides2025
Technical Presentation (July 2024)Technical27 slidesJul 10, 2024
Technical Presentation (2024)Technical20 slides2024
Corporate Update (July 2023)Corporate update24 slidesJul 26, 2023
ENDO 2022Conference15 slidesJun 11, 2022
All 11 decks
DeckKindSlidesDate
ENDO (Endocrine Society)Conference6 slides

Open Decks

Financings

RaiseDate
Public offering of common stock
Made bigger: US$500.2M · US$35.5 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Morgan Stanley (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead)
Use of proceeds: Pre-commercial activities for avexitide including manufacturing capacity, research and development, working capital and general corporate purposes
Aug 20, 2026
Public offering of common stock
Announced: US$175M · US$10 a share · Leerink Partners +2
Dealers: Leerink Partners (lead), Guggenheim Securities (lead), H.C. Wainwright & Co. (lead)
Use of proceeds: Avexitide commercial readiness, research and development, working capital and general corporate purposes
Sep 10, 2025
Public offering of common stock
Announced: about US$60M · US$3.5 a share · Leerink Partners
Dealers: Leerink Partners (lead)
Use of proceeds: Advance preparations for commercialization and pipeline programs, working capital and general corporate purposes
Jan 10, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$19.00 a share on Jan 6, 2022.

Price
US$19.00 a share
Shares offered
10,000,000 shares of common stock
Offering size
US$190 million
Underwriters' option
Up to 1,500,000 more shares
Underwriters
Goldman Sachs & Co. LLC, SVB Leerink, Evercore ISI, H.C. Wainwright & Co. · In the order on the cover
Shares delivered
On or about Jan 11, 2022

Steps

StepWhen
Draft sent to the SEC in confidenceApr 26, 2021
Filed publiclyDec 16, 2021
Amended onceJan 3, 2022
Shares registered with an exchangeJan 4, 2022
Declared effective by the SECJan 6, 2022
Final prospectus, with the priceJan 10, 2022

Open IPO · From the cover of the final prospectus (424B4) filed Jan 10, 2022

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue087.4M380.8M22.2M285.0K650.0K1.43M
Cost of revenue05.95M25.4M2.99M52.0K24.6M11.9M
Gross profit-525.0K45.2M355.3M19.2M285.0K-23.9M-10.5M
Research and development90.4M104.1M128.2M93.5M44.0M24.6M11.9M
Selling, general and administrative62.9M114.3M188.4M127.1M38.9M14.9M3.08M
Operating income-153.3M-314.7M38.8M-201.3M-82.7M-39.0M-13.6M
Depreciation and amortization525.0K904.0K1.09M487.0K52.0K1.00K13.6M
EBITDA-152.8M-313.8M39.9M-200.9M-82.6M-39.0M0
Interest expense4.29M36.0K2.29M1.28M
Income before tax-144.7M-302.1M54.3M-197.6M-87.9M-42.3M-13.7M
Income tax46.0K-393.0K5.03M774.0K-52.0K2.56M1.10M
Net income-144.7M-301.7M49.3M-198.4M-87.9M-42.3M-14.8M
Earnings per share, basic-1.53-4.430.73-3.39-13.35-0.75-0.26
Earnings per share, diluted-1.53-4.430.70-3.39-13.35

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents226.7M77.4M170.2M62.5M50.2M12.9M3.06M
Short-term investments90.3M99.1M201.2M284.4M45.9M0
Receivables88.0K447.0K40.0M15.3M0
Inventory038.3M9.77M0
Current assets323.7M189.4M464.7M382.1M105.0M13.6M3.20M
Property, plant and equipment310.0K961.0K2.69M2.61M474.0K151.0K
Total assets332.6M193.6M517.5M391.5M105.6M14.1M3.22M
Accounts payable3.52M2.94M22.1M6.26M4.37M3.61M2.19M
Current liabilities22.7M28.4M82.0M46.6M17.4M7.33M4.53M
Long-term debt1.43M14.9M
Total debt5.96M1.98M4.24M6.28M1.43M14.9M
Total liabilities27.4M28.9M84.0M50.8M17.4M80.8M28.6M
Shareholders' equity305.3M164.8M433.4M340.6M-151.2M-66.7M-25.4M
Shares outstanding109.9M68.6M67.7M66.5M7.02M56.5M56.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-123.3M-167.6M11.9M-179.9M-74.8M-36.7M-10.7M
Capital spending-138.0K-157.0K-1.24M-2.53M-353.0K-151.0K-151.0K
Free cash flow-123.5M-167.8M10.7M-182.4M-75.2M-36.8M-10.7M
Cash from investing14.0M75.7M92.1M-239.0M-46.4M-151.0K-151.0K
Cash from financing257.0M348.0K3.54M431.8M158.5M46.8M668.0K
Share buybacks-3.31M434.6M
Change in cash148.8M-92.1M107.7M12.9M37.3M9.97M3.09M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 7, 2026Insider tradeSEC
144 · Notice of proposed saleOct 5, 2026Other filingsSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
8-K · Current reportSep 8, 2026Material contractSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
8-K · Current reportAug 20, 2026Material contractSEC
424B5 · ProspectusAug 20, 2026Offer documentSEC
424B5 · ProspectusAug 18, 2026Offer documentSEC
8-K · Current reportAug 18, 2026Current reportSEC
8-K · Current reportAug 18, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
8-K · Current reportJun 4, 2026Meeting outcomeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
8-K · Current reportMar 24, 2026Current reportSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 3, 2026Offer documentSEC
S-3ASR · Registration statementMar 3, 2026Offer documentSEC
10-K · Annual reportMar 3, 2026Annual reportSEC
8-K · Current reportMar 3, 2026ResultsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJan 30, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
144 · Notice of proposed saleJan 16, 2026Other filingsSEC
144 · Notice of proposed saleJan 16, 2026Other filingsSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026Current reportSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeNov 17, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 7, 2025Big-stake noticeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
8-K · Current reportSep 10, 2025Material contractSEC
424B5 · ProspectusSep 10, 2025Offer documentSEC
424B5 · ProspectusSep 9, 2025Offer documentSEC
8-K · Current reportAug 27, 2025Current reportSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
144 · Notice of proposed saleAug 12, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 25, 2025Big-stake noticeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 5, 2025Meeting outcomeSEC
4 · Change in ownershipMay 27, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 24, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2025Meeting noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveMar 27, 2025Other filingsSEC
CORRESP · Letter to the SECMar 24, 2025Other filingsSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
UPLOAD · Letter from the SECMar 5, 2025Other filingsSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 4, 2025Offer documentSEC
S-3 · Registration statementMar 4, 2025Offer documentSEC
10-K · Annual reportMar 4, 2025Annual reportSEC
POSASRMar 4, 2025Other filingsSEC
8-K · Current reportMar 4, 2025ResultsSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 14, 2025Big-stake noticeSEC
8-K · Current reportJan 10, 2025Material contractSEC
424B5 · ProspectusJan 10, 2025Offer documentSEC
424B5 · ProspectusJan 10, 2025Offer documentSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
8-K · Current reportDec 30, 2024Current reportSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipNov 6, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 25, 2024Big-stake noticeSEC
8-K · Current reportOct 17, 2024Current reportSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 9, 2024Insider tradeSEC
4/A · Change in ownership, amendedSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
SC 13G · Big-stake noticeAug 26, 2024Big-stake noticeSEC

This page holds 200 of 448 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Amylyx Pharmaceuticals, Inc.’s releases · as of Oct 26, 2026

Common shares
128,562,904
Fully diluted
128,562,904

Fully diluted

LineSharesAs of
Common shares128,562,904Oct 26, 2026

Share count over time

CountShares
Oct 26, 2026128,562,904

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Fidelity19.9MUS$580MSep 30, 2026
Perceptive Advisors LLC10.6MUS$308MSep 30, 2026
BlackRock10.4MUS$302MSep 30, 2026
Vanguard7.17MUS$209MSep 30, 2026
TCG Crossover Management, LLC6.24MUS$182MSep 30, 2026
Driehaus Capital Management LLC5.43MUS$158MSep 30, 2026
Janus Henderson5.4MUS$157MSep 30, 2026
Saturn V Capital Management LP4.47MUS$130MSep 30, 2026
Ra Capital Management, L.P.4.28MUS$125MSep 30, 2026
First Light Asset Management, LLC3.99MUS$116MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Franklin Templeton3.93MUS$116MSep 30, 2026
T. Rowe Price3.84MUS$112MSep 30, 2026
Goldman Sachs3.59MUS$104MSep 30, 2026
JPMorgan3.43MUS$101MSep 30, 2026
Morgan Stanley2.79MUS$81.3MSep 30, 2026
State Street2.72MUS$79.1MSep 30, 2026
Geode Capital2.66MUS$77.4MSep 30, 2026
Siren, L.L.C.2.48MUS$72.2MSep 30, 2026
Commodore Capital LP2MUS$58.2MSep 30, 2026
683 Capital Management, LLC1.15MUS$33.5MSep 30, 2026
Woodline Partners LP1.15MUS$33.4MSep 30, 2026
DWS1.07MUS$31.2MSep 30, 2026
Northern Trust964KUS$28MSep 30, 2026
Schwab916KUS$26.7MSep 30, 2026
Elmind Capital, LP895KUS$26MSep 30, 2026
Boxer Capital Management, LLC893KUS$26MSep 30, 2026
Alyeska Investment Group, L.P.877KUS$25.5MSep 30, 2026
Rock Springs Capital Management LP757KUS$22MSep 30, 2026
Jane Street735KUS$21.4MSep 30, 2026
Great Point Partners LLC700KUS$20.4MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.680KUS$19.8MSep 30, 2026
Parkman Healthcare Partners LLC675KUS$19.6MSep 30, 2026
Two Sigma670KUS$19.5MSep 30, 2026
Adage Capital Partners Gp, L.L.C.600KUS$17.5MSep 30, 2026
Ikarian Capital, LLC561KUS$16.3MSep 30, 2026
Federated Hermes, Inc.533KUS$15.5MSep 30, 2026
D. E. Shaw & Co., Inc.516KUS$15MSep 30, 2026
Catalio Capital Management, LP506KUS$14.7MSep 30, 2026
Nuveen506KUS$14.7MSep 30, 2026
Citadel489KUS$14.2MSep 30, 2026
Bank of America416KUS$12.1MSep 30, 2026
Point72 Asset Management, L.P.389KUS$11.3MSep 30, 2026
Marshall Wace, LLP377KUS$11MSep 30, 2026
ADAR1 Capital Management, LLC367KUS$10.7MSep 30, 2026
First Trust342KUS$9.95MSep 30, 2026
Ensign Peak Advisors, Inc338KUS$9.83MSep 30, 2026
UBS336KUS$9.78MSep 30, 2026
Cormorant Asset Management, LP300KUS$8.73MSep 30, 2026
Affinity Asset Advisors, LLC300KUS$8.73MSep 30, 2026
BNY294KUS$8.56MSep 30, 2026

This page holds 50 of 221 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund3.15MUS$56.7MJun 30, 2026
Fidelity Advisor Biotechnology Fund2.43MUS$49.4MJul 31, 2026
iShares Russell 2000 ETF2.36MUS$42.4MJun 30, 2026
Fidelity Small Cap Growth Fund2.12MUS$43MJul 31, 2026
Select Health Care Portfolio1.42MUS$20.4MMay 31, 2026
Eventide Healthcare & Life Sciences Fund1.32MUS$23.8MJun 30, 2026
Fidelity Stock Selector Small Cap Fund1.26MUS$25.5MJul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1.14MUS$16.3MMay 31, 2026
Select Biotechnology Portfolio1.1MUS$15.7MMay 31, 2026
Fidelity Small Cap Growth K6 Fund1.05MUS$21.4MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Small Cap Index Fund1.01MUS$20.5MJul 31, 2026
Fidelity Series Small Cap Opportunities Fund1.01MUS$20.4MJul 31, 2026
Vanguard Extended Market Index Fund963KUS$17.3MJun 30, 2026
Fidelity Balanced Fund880KUS$12.6MMay 31, 2026
iShares Russell 2000 Growth ETF849KUS$15.2MJun 30, 2026
JPMorgan Small Cap Growth Fund799KUS$14.4MJun 30, 2026
Franklin Biotechnology Discovery Fund753KUS$15.3MJul 31, 2026
Franklin Small Cap Growth Fund744KUS$15.1MJul 31, 2026
Fidelity Advisor Health Care Fund715KUS$14.5MJul 31, 2026
iShares Biotechnology ETF658KUS$11.8MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF486KUS$8.72MJun 30, 2026
Vanguard Russell 2000 Index Fund469KUS$6.74MMay 31, 2026
Fidelity Extended Market Index Fund431KUS$6.18MMay 31, 2026
Schwab U.S. Small-Cap ETF403KUS$5.78MMay 31, 2026
Fidelity U.S. Equity Central Fund380KUS$6.82MJun 30, 2026
Fidelity Small Cap Value Fund360KUS$7.31MJul 31, 2026
Fidelity Growth Company Fund342KUS$4.9MMay 31, 2026
BlackRock Advantage Small Cap Core Fund307KUS$4.41MMay 29, 2026
Driehaus Micro Cap Growth Fund280KUS$5.03MJun 30, 2026
VIP Health Care Portfolio260KUS$4.67MJun 30, 2026
Select Pharmaceuticals Portfolio258KUS$3.7MMay 31, 2026
JPMorgan Small Cap Blend Fund254KUS$4.56MJun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund246KUS$4.42MJun 30, 2026
U.S. Micro Cap Portfolio246KUS$4.99MJul 31, 2026
Schwab Small-Cap Index Fund223KUS$4.54MJul 31, 2026
iShares U.S. Pharmaceuticals ETF220KUS$3.94MJun 30, 2026
Vanguard Explorer Fund209KUS$4.25MJul 31, 2026
U.S. Small Cap Portfolio199KUS$4.04MJul 31, 2026
Vanguard Health Care Index Fund198KUS$2.84MMay 31, 2026
First Trust Small Cap Growth AlphaDEX Fund195KUS$3.97MJul 31, 2026
Federated Hermes MDT Small Cap Growth Fund177KUS$3.6MJul 31, 2026
Fidelity Small Cap Discovery Fund172KUS$3.49MJul 31, 2026
Master Small Cap Index Series172KUS$3.09MJun 30, 2026
Fidelity Total Market Index Fund160KUS$2.29MMay 31, 2026
Dimensional U.S. Small Cap ETF148KUS$3.02MJul 31, 2026
Vanguard U.S. Momentum Factor ETF145KUS$2.09MMay 31, 2026
Fidelity Series Small Cap Discovery Fund137KUS$2.78MJul 31, 2026
Adara Smaller Companies Fund136KUS$1.95MMay 31, 2026
Fidelity Series Total Market Index Fund127KUS$1.82MMay 31, 2026
Fidelity Series All-Sector Equity Fund123KUS$2.5MJul 31, 2026

This page holds 50 of 186 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Frates James M
Officer: Chief Financial Officer
Sale12,800USD 30.32US$388KNov 10, 2026
Frates James M
Officer: Chief Financial Officer
Sale7,200USD 30.97US$223KNov 10, 2026
Cohen Joshua B
Director, Officer: Co-Chief Executive Officer
Sale38,105USD 29.39US$1.12MNov 9, 2026
Cohen Joshua B
Director, Officer: Co-Chief Executive Officer
Sale61,895USD 30.11US$1.86MNov 9, 2026
Klee Justin B.
Director, Officer: Co-Chief Executive Officer
Sale37,483USD 29.39US$1.1MNov 9, 2026
Klee Justin B.
Director, Officer: Co-Chief Executive Officer
Sale62,517USD 30.11US$1.88MNov 9, 2026
Frates James M
Officer: Chief Financial Officer
Sale7,700USD 29.39US$226KNov 9, 2026
Frates James M
Officer: Chief Financial Officer
Sale12,300USD 30.11US$370KNov 9, 2026
Milne George M Jr
Director
Sale30,000USD 27.70US$831KOct 5, 2026
Klee Justin B.
Director, Officer: Co-Chief Executive Officer
Sale29,025USD 32.13US$933KSep 10, 2026
All 22 trades
TradeTradeSharesPriceValueDate
Klee Justin B.
Director, Officer: Co-Chief Executive Officer
Sale1,439USD 33.16US$47,717Sep 10, 2026
Cohen Joshua B
Director, Officer: Co-Chief Executive Officer
Sale29,545USD 32.16US$950KSep 10, 2026
Cohen Joshua B
Director, Officer: Co-Chief Executive Officer
Sale919USD 33.15US$30,465Sep 10, 2026
Mazzariello Gina
Officer: Chief Legal Officer
Sale9,525USD 32.46US$309KSep 10, 2026
Mazzariello Gina
Officer: Chief Legal Officer
Sale11USD 33.34US$367Sep 10, 2026
Frates James M
Officer: Chief Financial Officer
Sale9,768USD 32.27US$315KSep 10, 2026
Frates James M
Officer: Chief Financial Officer
Sale1,042USD 33.23US$34,626Sep 10, 2026
Bedrosian Camille L
Officer: Chief Medical Officer
Sale7,947USD 32.21US$256KSep 10, 2026
Bedrosian Camille L
Officer: Chief Medical Officer
Sale2,081USD 33.09US$68,860Sep 10, 2026
Mazzariello Gina
Officer: Chief Legal Officer
Sale15,000USD 17.61US$264KJul 10, 2026
Mazzariello Gina
Officer: Chief Legal Officer
Sale15,000USD 18.32US$275KJul 9, 2026
Firestone Karen
Director
Buy3,800USD 13.51US$51,338May 21, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC15.00%16.5MDec 31, 2025Schedule 13G
Perceptive Advisors LLC8.20%10.6MSep 30, 2026Schedule 13G
BlackRock, Inc.7.10%7.78MDec 31, 2025Schedule 13G
TCG Crossover GP II, LLC5.70%6.24MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Paul Fonteyne
Other companies: Apnimed, Inc. (Director · Since at least Jul 30, 2026); Apellis Pharmaceuticals, Inc. (Director · Since at least Apr 2, 2020); Covetrus Inc (Director · Jul 1, 2021 – Oct 13, 2022 · Past); AMAG Pharmaceuticals Inc (Director · Oct 8, 2019 – Nov 16, 2020 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past)
Director · Since at least Jan 6, 2022
Camille L. Bedrosian
Other companies: Rhythm Pharmaceuticals, Inc. (Director · Since at least Dec 9, 2020); Crinetics Pharmaceuticals, Inc. (Director · Since at least Sep 1, 2020); Ultragenyx Pharmaceutical Inc. (EVP and Chief Medical Officer · Jan 29, 2018 – Mar 1, 2023 · Past); Ariad Pharmaceuticals Inc (VP, Chief Medical Officer · Apr 16, 2007 – Apr 16, 2007 · Past)
Chief Medical Officer · Since at least Nov 27, 2023
Bernhardt G. Zeiher
Other companies: Abeona Therapeutics Inc. (Director · Since at least Aug 8, 2024); Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Apr 4, 2023)
Director · Since at least Mar 14, 2024
Daphne Quimi
Other companies: Century Therapeutics, Inc. (Director · Since at least Oct 1, 2022); Amicus Therapeutics Inc (Chief Financial Officer · Oct 1, 2020 – Jan 17, 2023 · Past)
Director · Since at least Jan 6, 2022
George M Milne Jr
Other companies: Charles River Laboratories International, Inc. (Director · Mar 1, 2021 – May 7, 2021 · Past); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2023 · Past)
Director · Since at least Jan 6, 2022
James M. Frates
Other companies: Sage Therapeutics Inc (Director · Since at least Jul 17, 2014); Alkermes plc (SVP, Alks Inc; CFO ALKS · May 2, 2006 – May 14, 2020 · Past)
Chief Financial Officer · Since at least Jan 6, 2022
Dan MonahanChief Commercial Officer · Since at least Mar 4, 2025
George MilneChairman · Since at least Oct 7, 2026
Gina M. MazzarielloChief Legal Officer & General Counsel · Since at least Feb 22, 2022
Josh CohenCo-CEO of Amylyx · Since at least Sep 14, 2026
All 18 people
PersonSeat
Joshua B CohenCo-Chief Executive Officer, Director · Since at least Jan 6, 2022
Justin KleeCo-CEO of Amylyx · Since at least Jan 6, 2022
Karen FirestoneDirector · Since at least Mar 16, 2023
Kari FirestoneDirector · Since at least Nov 5, 2026
Linda A. ArsenaultChief Human Resources Officer · Since at least Nov 5, 2026
Margaret OlingerChief Commercial Officer · Jan 6, 2022 – Dec 27, 2023 · Past
Patrick D YeramianChief Medical Officer · Jan 6, 2023 – Jan 9, 2024 · Past
Tom HolmesChief Technical Operations Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Amylyx Pharmaceuticals, Inc.